The Novel Monoclonal Antibody HPC2 and N-Cadherin Distinguish Pancreatic Ductal Adenocarcinoma From Cholangiocarcinoma

Human Pathology - United Kingdom
doi 10.1016/j.humpath.2011.11.012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Antiproliferative Effects of Monoclonal Antibodies Against (Pro)renin Receptor in Pancreatic Ductal Adenocarcinoma

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Pancreatic Ductal Adenocarcinoma With Cystic Features

HPB
HepatologyGastroenterology
2016English

Immunohistochemical Expression of NEDD9, E-Cadherin and Γ-Catenin and Their Prognostic Significance in Pancreatic Ductal Adenocarcinoma (PDAC)

Bosnian Journal of Basic Medical Sciences
Medicine
2018English

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

Tumor-Stroma Interactions in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Pancreatic Ductal Adenocarcinoma inBRCA2mutation Carriers: Table 1

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2016English

Features of Immunophenotype of Pancreatic Ductal Adenocarcinoma

Zaporozhye Medical Journal
2014English

The Characterization of “Islet Invasion” in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

MEX3A Knockdown Inhibits the Development of Pancreatic Ductal Adenocarcinoma

Cancer Cell International
Cancer ResearchOncologyGenetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy